Short answer
Axsome Therapeutics, Inc. (AXSM) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA approval expands AUVELITY into Alzheimer’s-related dementia agitation.
Axsome Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA approval expands AUVELITY into Alzheimer’s-related dementia agitation
- New indication broadens Axsome’s commercial opportunity beyond existing uses
- Approval may support additional revenue growth and strengthen AUVELITY’s market position
- Investors should assess launch timing, pricing, reimbursement, and commercial uptake in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- FDA approval expands AUVELITY into Alzheimer’s agitation, adding a second indication to its existing major depressive disorder use
- First-in-class treatment targeting NMDA and sigma-1 receptors in a large underserved population exceeding 7 million U.S. Alzheimer’s patients
- Approval supported by Phase 3 ADVANCE-1 efficacy and ACCORD-2 relapse-delay data, strengthening commercial launch credibility
- ADVANCE-1 discontinuations due to adverse events matched placebo at 1.3%, with dizziness and dyspepsia the most common reactions
- Immediate launch with patient support, payer authorization assistance, and savings programs; commercial uptake and reimbursement remain key execution variables
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Axsome Therapeutics, Inc. 8-K filings
Get the next AXSM 8-K as it lands
Follow AXSM for push alerts, or ask the research agent what this filing means.